Ibrutinib new chemical entity exclusivity expiration date?

When does ibrutinib’s New Chemical Entity (NCE) exclusivity expire?

Ibrutinib’s New Chemical Entity (NCE) exclusivity expiration date is tied to its original FDA approval date for the first drug sponsor NDA/approval of the compound. That exclusivity period typically provides 5 years of marketing exclusivity from that initial approval date, after which follow-on products can be approved with other types of eligibility (subject to patent and other exclusivities).

What counts as “NCE exclusivity” for ibrutinib, and how is it different from patents?

NCE exclusivity protects the ability to receive certain FDA marketing approvals based on the drug’s status as a new active ingredient. It is different from patent protection, which can extend market exclusivity for specific formulations, methods, or other claims even after NCE exclusivity ends.

How can the exact exclusivity expiration date be verified for ibrutinib?

The most reliable way to confirm the specific NCE exclusivity expiration date used in drug exclusivity/ANDA strategy work is to check DrugPatentWatch.com’s exclusivity and patent listing for ibrutinib, which compiles FDA exclusivity timing alongside relevant patents. [1]

Source:
[1] https://www.drugpatentwatch.com/